Bouraoui Yosra, Ricote Mónica, García-Tuñón Ignacio, Rodriguez-Berriguete Gonzalo, Touffehi Mounir, Rais Nawfel Ben, Fraile Benito, Paniagua Ricardo, Oueslati Ridha, Royuela Mar
Department of Cell Biology and Genetics, University of Alcalá, E-28871 Alcalá de Henares, Madrid, Spain.
Cancer Detect Prev. 2008;32(1):23-32. doi: 10.1016/j.cdp.2008.02.007. Epub 2008 Apr 9.
The aim of this study was to relate the expression, analyzed by Western blot and immunohistochemistry, of several pro-inflammatory cytokines, including IL-1, IL-6 and TNF-alpha, with serum levels of prostate-specific antigen (PSA) in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression. We are also discussing the possible use of these cytokines as a potential therapeutic target.
The study was carried out in 5 normal, 25 benign prostatic hyperplastic (BPH) and 17 cancerous human prostates (PC). Immunohistochemical and Western blot analysis were performed. Serum levels of PSA were assayed by an immulite autoanalyzer.
The most relevant results showed that in BPH, IL-1alpha, IL-6 and tumor necrosis factor (TNF) were only expressed in patients with PSA serum levels of 0-4 or 4-20 ng/ml, but not in the group >20 ng/ml. In PC these cytokines were only expressed in patients with PSA serum levels >4 ng/ml.
In PC there was an association between the high expression of pro-inflammatory cytokines (TNFalpha, IL-6, IL-1), elevated serum levels of PSA and cancer progression. A better understanding of the biologic mechanism of this association may provide new targets for therapy in these patients.
本研究旨在通过蛋白质印迹法和免疫组织化学分析,探究包括白细胞介素-1(IL-1)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)在内的多种促炎细胞因子的表达与正常及病理状态(增生和癌症)前列腺组织中前列腺特异性抗原(PSA)血清水平之间的关系,以阐明它们在肿瘤进展中可能发挥的作用。我们还在讨论将这些细胞因子用作潜在治疗靶点的可能性。
该研究对5例正常前列腺、25例良性前列腺增生(BPH)和17例前列腺癌(PC)患者的前列腺组织进行。进行了免疫组织化学和蛋白质印迹分析。通过免疫发光自动分析仪检测PSA血清水平。
最相关的结果显示,在BPH中,IL-1α、IL-6和肿瘤坏死因子(TNF)仅在PSA血清水平为0 - 4或4 - 20 ng/ml的患者中表达,而在PSA血清水平>20 ng/ml的组中未表达。在PC中,这些细胞因子仅在PSA血清水平>4 ng/ml的患者中表达。
在PC中,促炎细胞因子(TNFα、IL-6、IL-1)的高表达、PSA血清水平升高与癌症进展之间存在关联。更好地理解这种关联的生物学机制可能为这些患者提供新的治疗靶点。